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Abstract Clinical multidrug resistance is caused by a group of
integral membrane proteins that transport hydrophobic drugs
and lipids across the cell membrane. One class of these perme-
ases, known as multidrug resistance ATP binding cassette
(ABC) transporters, translocate these molecules by coupling
drug/lipid e¥ux with energy derived from the hydrolysis of
ATP. In this review, we examine both the structures and con-
formational changes of multidrug resistance ABC transporters.
Together with the available biochemical and structural evidence,
we propose a general mechanism for hydrophobic substrate
transport coupled to ATP hydrolysis.
& 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Multidrug resistance (MDR) is a signi¢cant challenge in the
treatment of infectious diseases and cancer. The World Health
Organization has reported that MDR bacteria can account
for up to 60% of all hospital acquired infections globally
[1]. Drug resistant bacterial strains that cause gonorrhea,
pneumonia, cholera, and tuberculosis are widespread and
are di⁄cult to treat [2]. In humans, a similar mechanism of
MDR is a major reason for the failure of several chemother-
apeutics in the treatment of cancers. Tumor cells that are
initially sensitive to a broad range of drugs can frequently
reemerge and become resistant to entire families of anti-cancer
drugs. Patients with these tumors often have severe relapse
with few medical alternatives to improve their health condi-
tion.
2. The multidrug transporters
A major cause of bacterial and cancer drug resistance is
attributed to a robust array of MDR transporters that extrude
drug compounds out of the cell. MDR transporters can be
divided into two classes based on their source of energy: Sec-
ondary transporters, which use proton gradients to facilitate
an antiporter mechanism, and adenosine triphosphate (ATP)
binding cassette (ABC) transporters that couple the hydrolysis
of ATP to substrate transport across the cell membrane. Sec-
ondary MDR transporters are comprised of four superfami-
lies: the resistance/nodulation/division family, the multidrug/
oligosaccharidyl-lipid/polysaccaharide £ippase family, the
drug/metabolite transporter superfamily, and the highly di-
verse major facilitator superfamily [3]. ABC transporters be-
long to one of the largest superfamilies of proteins and that
either import or export a broad range of substrates that in-
clude amino acids, ions, sugars, lipids, and drugs [4^7]. The
di¡erences in their substrate speci¢cities are re£ected in their
overall divergence in their transmembrane domains (TMDs).
While bacteria genomes encode both classes of ABC proteins,
eukaryotes have only exporters suggesting an early evolution-
ary divergence of their TMDs. In humans, 46 ABC transport-
ers have been identi¢ed and play important roles in human
diseases, which include cystic ¢brosis, macular dystrophy, and
several neurological disorders [8].
All ABC transporters are composed minimally of two nu-
cleotide binding domains (NBDs) and two TMDs [9]. The
NBD, which is also called an ABC, is the hallmark feature
of this transporter family. The high-resolution structures of
isolated NBDs have been multiply determined and are similar
[10^13]. The role of the TMD is to recognize and mediate the
passage of substrates across the cell membrane. For ABC
transporters that permeate hydrophilic molecules, the TMD
shields substrates from the lipids making up the bilayer by
providing a hydrophilic pathway across the cell membrane.
In most cases, these permeases have speci¢c substrate specif-
icities and may require a periplasmic binding protein to facil-
itate transport. The TMD for drug and lipid £ippases, in
contrast, are capable of recognizing and removing a large
number of chemically unrelated lipids and toxins directly
from the cell membrane. Many of these transporters trans-
locate useful cytotoxins such as anti-cancer drugs [14].
Perhaps the most widely studied MDR-ABC transporter is
the P-glycoprotein or human MDR1/ABCB1 [15]. First dis-
covered in the early 1970s, this MDR-ABC transporter has
been proposed to act as ‘hydrophobic vacuum cleaner’ be-
cause of its ability to remove both lipids and drugs as they
intercalate and di¡use through the cell membrane [16,17]. The
protein sequences of lipid and drug ABC transporters are
similar and probably re£ect a common transport mechanism.
Human MDR3, for example, is a well-characterized phospha-
tidyl-choline £ippase and has 73% protein sequence identity to
human MDR1. In fact, human MDR1 is itself a lipid £ippase
transporting short chain phospholipids. Although the mecha-
nism for ATP hydrolysis for most if not all ABC transporters
is probably conserved, the details underlying the structural
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basis coupling this energy to substrate transport is likely dif-
ferent between ABC exporters that transport hydrophobic
substrates and importers that permeate water-soluble mole-
cules [18]. How do MDR-ABC transporters translocate drugs
and lipids from the inner to the outer cell membrane lea£et?
3. Low-resolution cryo-electron microscopy (EM) studies of
MDR-ABC transporters
Historically, our understanding of drug transporter struc-
ture originated from single particle and 2D cryo-EM of hu-
man MDR1 [19]. In their work, a 25 AS resolution structure
revealed a large aqueous chamber spanning the cell membrane
with no evidence of close contacts between NBDs. Later, sim-
ilar studies revealed human MDR1 trapped in distinct cata-
lytic states showing dramatic rearrangements of the TMD
during the transport cycle. Although the precise boundaries
of the TMD and NBD components could not be resolved, the
structures showed a substantial opening in the plane of the
cell membrane leading into the chamber, suggesting that sub-
strates could be directly accepted from the lipid bilayer. The
existence of such a chamber within the bilayer supported a
‘£ippase’ model for human MDR1 and other MDR-ABC
transporters [20]. Since then, other EM structures of MDR-
ABC transporters have demonstrated that these proteins can
undergo signi¢cant conformational changes in both their
TMD and NBD. The 3D cryo-EM structure of YvcC from
Bacillus subtilis shows an ‘open’ conformation and compares
well with the X-ray structure of Eco-MsbA [21]. The projec-
tion structure of the MRP1/ABCC1 reveals a dimer with each
half of the monomer related by a pseudo two-fold axis in
projection [22].
4. The MsbA MDR-ABC transporter homologs
The structures of the open and closed conformations of
MsbA reveal large conformational changes and suggest a gen-
eral transport mechanism for hydrophobic substrates [23,24].
MsbA is a lipid £ippase that transports lipid A, a major
component in the bacterial outer membrane [25]. Studies in
vitro demonstrate that MsbA is an ATPase that is speci¢cally
stimulated by lipid A [26]. Loss of MsbA from the cell mem-
brane or mutations that disrupt transport results in the lethal
accumulation of lipid A in the inner cell membrane [27,28].
MsbA is the only essential ABC transporters in prokaryotes
and is conserved in every bacterium with more than 30 ortho-
logs identi¢ed. MsbA is a close bacterial homolog of human
MDR1 by protein sequence homology and has overlapping
substrate speci¢cities with the MDR-ABC transporter LmrA
from Lactococcus lactis [29]. MsbA from Escherichia coli, for
example, is 36% identical to the NH2-terminal half of human
MDR1, suggesting a common evolutionary origin for the me-
chanics of hydrophobic substrate transport.
The overall structural organization of MsbA is similar to
human MDR1, which has the TMD fused with the NBD into
a single polypeptide. The MsbA gene, however, encodes only
a half transporter that assembles to form a homodimer with a
total molecular mass of V130 kDa. The X-ray structures of
both the open and closed conformation of MsbA validate the
dimer con¢guration and reveals a chamber formed from 12
transmembrane K-helices. The openings of the chamber are
de¢ned by intermolecular contacts between TM2 from one
monomer and TM5 from another. The chamber is lined
with charged and polar residues that are likely solvated creat-
ing an energetically unfavorable microenvironment for hydro-
Fig. 1. Structure of MsbA. Views of MsbA in the open (left) and closed (right) conformation looking into the chamber opening (side view)
and from the extracellular side (top view). The TMD, ICD, and NBD are colored red, dark blue, and cyan, respectively. The loop connecting
the TMD with the ICD observed in the closed conformation from V. cholerae (right) is highlighted in green and the loop connecting the K and
L domain of the NBD is shown in orange. The approximate position of the membrane bilayer is indicated by black lines.
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phobic substrates. Faced with the charge and highly polar
contribution of bound solvent, we propose that lipid A and
other hydrophobic molecules ‘£ip’ into an energetically more
favorable position within the outer membrane lea£et.
Another distinct feature of MDR-ABC transporters is a
conserved region located between the TMD and NBD, which
we collectively call the intracellular domain (ICD). The struc-
tures of MsbA reveal that this region is helical and likely
functions to couple the TMD to the NBD. ICD1 (residues
97^139) is in contact with the NBD and forms a U-like struc-
ture consisting of three K-helices. The second helix of ICD1
serves as a conserved pivot about which the NBD could ro-
tate. The vitamin B12 importer BtuCD also has an analogous
contact mediating energy transduction from the NBD to the
TMD [30]. The tether joining the TMD with the NBD is
clearly resolved in the closed conformation structure of
MsbA (highlighted in green, Fig. 1). This peptide linker allows
the NBD to disassociate and dimerize to form an ATP-com-
petent state.
5. Possible general mechanism for MDR-ABC transporters
MDR-ABC transporters are unique because they extract
lipid/drug molecules as they di¡use through the cell mem-
brane and either £ip them to the outer lea£et or expel them
into the extracellular milieu. In order to accomplish this, they
must ¢rst recognize substrates, and then sequester it from the
membrane in a microenvironment that preferentially favors its
movement to the outer membrane lea£et. The ‘£ipping cham-
ber’ formed from the two halves of the transporter spanning
the cell membrane is seen in both the open and closed con-
formations of MsbA, giving merit to the notion that the
TMDs are a structurally conserved architecture. The position
of NBDs between the two structures, however, is rotated sub-
stantially while sharing the same point of contact in the TMD
(residues 113^119). An analogous contact is observed in the
vitamin B12 ABC importer and probably represents a funda-
mental feature in all ABC transporters.
The structures of MsbA from Vibrio cholerae and E. coli
demonstrate that the NBDs can sample a large conformation-
al space in the absence of nucleotides and is consistent with
cross-linking studies of human MDR1 suggesting that TM6,
which is physically tethered to the NBD, rotates during the
catalytic cycle [31]. For example, recent cryo-EM studies of
the MsbA homolog YvcC reveal that the NBD can disengage
from the ICD during the catalytic cycle [32]. The 3D recon-
struction of the yeast MDR-ABC transporter Pdr5p reveals a
closely packed arrangement and a structural organization
such that the orientations of the two NBDs are perpendicular
within a monomer [33]. The existence of di¡erent angular
positions of the NBDs with respect to the Pdr5p’s TMDs
suggests large rotational movements during the transport
cycle. Unlike importers, ABC exporters have evolved to fuse
the TMD with the NBD, to ensure a physically tethered cata-
lytic domain. The presence of the peptide tether would allow
the NBD to dissociate from ICD1 in the absence of substrate.
Upon substrate binding, conformational changes in ICD1
may increase its a⁄nity for the NBD such that it greatly
favors an orientation that promotes NBD dimerization driv-
ing chamber closure and ATP hydrolysis. This conformational
transition would ensure substrate recognition and ATP hydro-
lysis, which is tightly regulated.
Conformational changes in the NBD may add another level
of control for ATP hydrolysis. The recent X-ray structures of
the glucose ABC domain from Sulfolobus solfataricus, for ex-
ample, show signi¢cant rearrangement of domains within the
NBD between the nucleotide-bound and nucleotide-free states
[34]. While the L domain of the NBD was disordered in the
open conformational MsbA structure, it is clearly resolved in
the VC-MsbA crystal form (Fig. 1). This structure, however,
reveals that in the absence of nucleotides, the K and L do-
mains are loosely associated but folded. The K and L domains
are connected by a loop region that is less conserved among
ABC proteins (highlighted in orange, in Fig. 1). This confor-
mation has not been observed in previously solved structure
of isolated NBD and gives rise to a couple interpretations.
One possibility is that the separation of the K and L domains
may represent a potential NBD conformation in the absence
of nucleotides and can occur within the context of the TMDs.
Clearly, the separation of the K and L domains is possible for
the NBD alone. The NBD of the Rad50 ATPase enzyme, for
example, is formed from K and L domains that are from two
separate polypeptides that fold independently and associate to
form a catalytically active NBD [35]. This raises the intriguing
possibility that the interactions of NBD with the TMD upon
substrate binding could act to stabilize the association of the
domains favoring the ATP-bound state. An alternative possi-
bility is that the separation of the domains is a consequence of
crystal packing. Crystals of VC-MsbA, however, are sensitive
to several non-hydrolyzable nucleotide analogs at micromolar
concentrations. The disruption in the crystal lattice contacts is
likely due to the association of the K and L domains to form
the ATP-competent state (see Fig. 2). The structures of addi-
tional MsbA structures will reveal other possible structural
con¢gurations.
In our previous work, we presented a putative mechanism
where upon binding lipid A, MsbA adopts a closed confor-
mation that traps it within the chamber. This rearrangement
could be driven by the ATP-mediated dimerization of the
NBDs. There is signi¢cant biochemical evidence from studies
of human MDR1 and LmrA indicating their NBDs interact
during the transport cycle [36,37]. Indeed, the structures of the
Rad50 and MJ0796 show the formation of a stable dimer
upon binding ATP [38]. Biochemical studies of MsbA and
human MDR1 indicate that substrate recognition stimulates
ATP binding and hydrolysis by the NBD. In fact, ATP bind-
ing and hydrolysis are thought to be independent events and
have been shown to be associated with distinct conformation
states of human MDR1 [39,40]. Therefore, it is reasonable to
propose that binding of ATP to the NBDs triggers their di-
merization and results in the movement of transmembrane K-
helices. The formation of the NBD dimer may represent the
‘power stroke’ of MsbA that drives chamber closure to ‘£ip’
the lipid from the inner to the outer membrane lea£et. Upon
doing so, the chamber then opens to release the substrate (Fig.
2). Indeed, recent cryo-EM studies of MsbA from V. cholerae
in the presence of ADP show the opening of TMD allowing
substrate expulsion into the outer lea£et of the bilayer (per-
sonal communication from A. Ward and R. Milligan, to be
published).
The structure of the open and closed conformation of
MsbA represent two snapshots of an ABC exporter and fur-
ther substantiates the notion that MDR-ABC transporters are
molecular machines that scan the lower bilayer lea£et for
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substrates, accept them laterally into a chamber, and £ip them
to the outer membrane lea£et. Both structures give new in-
sights into the conformational possibilities and provide a
structural basis for the mechanism associate with lipid/drug
‘£ip^£op’. Taken together with the available biochemical evi-
dence and EM studies, the X-ray structures of MsbA shed
light on the molecular structural basis of drug transport by
MDR-ABC transporters. Clearly, more high-resolution struc-
tures of MsbA and other MDR-ABC transporters are needed
to fully understand the structural mechanisms underlying
drug/lipid transport across the cell membrane.
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Fig. 2. In the nucleotide-free resting state, MsbA oscillates between
conformational states where the tethered NBDs dissociate from
ICD1 and are free to rotate relative to the TMD. Substrate recogni-
tion at the chamber opening induces nucleotide binding by the
NBDs with an equal probability for either site as indicated (1). The
binding of nucleotide changes their conformation and promotes the
formation of an NBD dimer. Dimerization of the NBDs is the
‘power stroke’ of the transport cycle and drives recruitment of the
substrate into the chamber, where it £ips spontaneously to its new
location. The NBD dimer then cooperatively hydrolyzes ATP to
form the high-energy ADP+Pi intermediate (2). Conformational
shifts in the NBD dimer upon nucleotide hydrolysis are relayed
through the ICD causing the TMD to open, releasing the substrate
into the outer membrane lea£et. Relaxation of the high-energy inter-
mediate (3) causes the NBDs to disassociate and resets the TMD to
the resting state. The ¢gure is reproduced with permission [24].
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